RE: The Bull Run to £ 18 Short Term20 Aug 2021 10:27
Suitable PE.
Well thats literally the £54 question isnt it? So the market looked at NOVA - to the moon valuation, then retracted as it became clear to everyone it was a one hit wonder, then fell heavily as the market was informed that even the DHSC didnt want the product (or in fact utilise it correctly) so PE went 20 down to 5 down to 2.
Now as testing becomes systemic, especially for travel, Delta is pandemic, and the one off opportunity looks like a 2 or 3 off, the PE is rising again as future earnings become more likely.
Ages ago, and i cant be bothered to find the thread, i said that if testing for travel becomes mandatory and NOVA can grab a decent part of this market, then the valuation would be £50-£75 a share at 20x earnings longer term, not next month or anything, and if they have reasonable % of US business, then a NASDAQ listing would take them there.
But yes thats a long way from here - but not fantasy.
70m shares at £70 a share is £4.9 billion - at 20x PE needs £245m of earnings to produce .
Thats the target, as long as top line revenue and bottom line earnings keep on going at say +25% each year then we are in the right share. Thanks Blue